Cambium Bio Ltd
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing i… Read more
Cambium Bio Ltd (CMB) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -1.444x
Based on the latest financial reports, Cambium Bio Ltd (CMB) has a cash flow conversion efficiency ratio of -1.444x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-2.65 Million) by net assets (AU$1.84 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cambium Bio Ltd - Cash Flow Conversion Efficiency Trend (1999–2025)
This chart illustrates how Cambium Bio Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Cambium Bio Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cambium Bio Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Heart Test Laboratories Inc. Common Stock
NASDAQ:HSCS
|
-558.107x |
|
Jufan Industrial Co., Ltd.
TWO:4584
|
-0.004x |
|
Wijaya Karya Bangunan Gedung Tbk PT
JK:WEGE
|
-0.007x |
|
Cara Therapeutic
NASDAQ:CARA
|
0.880x |
|
TEKMAR GROUP PLC LS-01
F:6UA
|
N/A |
|
Gihon Telekomunikasi Indonesia Tbk PT
JK:GHON
|
0.046x |
|
Komputronik S.A.
WAR:KOM
|
-0.008x |
|
Elah Holdings Inc
PINK:ELLH
|
-0.073x |
Annual Cash Flow Conversion Efficiency for Cambium Bio Ltd (1999–2025)
The table below shows the annual cash flow conversion efficiency of Cambium Bio Ltd from 1999 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$1.84 Million | AU$-5.24 Million | -2.856x | -4986.40% |
| 2024-06-30 | AU$2.78 Million | AU$-155.86K | -0.056x | -116.58% |
| 2023-06-30 | AU$-1.95 Million | AU$-660.46K | 0.339x | +110.13% |
| 2022-06-30 | AU$1.07 Million | AU$-3.59 Million | -3.341x | -672.70% |
| 2021-06-30 | AU$4.15 Million | AU$2.42 Million | 0.583x | +132.85% |
| 2020-06-30 | AU$1.09 Million | AU$-1.94 Million | -1.776x | -414.34% |
| 2019-06-30 | AU$-6.39 Million | AU$-3.61 Million | 0.565x | +138.87% |
| 2018-06-30 | AU$2.92 Million | AU$-4.25 Million | -1.454x | -428.22% |
| 2017-06-30 | AU$8.10 Million | AU$3.59 Million | 0.443x | +194.04% |
| 2016-06-30 | AU$4.78 Million | AU$-2.25 Million | -0.471x | +34.23% |
| 2015-06-30 | AU$8.27 Million | AU$-5.92 Million | -0.716x | +4.65% |
| 2014-06-30 | AU$8.31 Million | AU$-6.24 Million | -0.751x | -146.66% |
| 2013-06-30 | AU$-2.87 Million | AU$-4.62 Million | 1.610x | +206.69% |
| 2012-06-30 | AU$1.95 Million | AU$-2.94 Million | -1.509x | -372.04% |
| 2011-06-30 | AU$3.29 Million | AU$-1.05 Million | -0.320x | -338.79% |
| 2002-06-30 | AU$40.54 Million | AU$5.43 Million | 0.134x | -31.25% |
| 2001-06-30 | AU$196.21 Million | AU$38.20 Million | 0.195x | -35.02% |
| 2000-06-30 | AU$161.09 Million | AU$48.26 Million | 0.300x | +17.02% |
| 1999-06-30 | AU$130.56 Million | AU$33.43 Million | 0.256x | -- |